Forticell Bioscience Inc – October 19,2006 (October 20th, 2006)
Reference is made to the letter agreement dated December 13,2004 from Paul Royalty Fund, L.P. (formerly known as Paul Capital Royalty Acquisition Fund, L.P., "PRF') to Ortec International, Inc. ("Ortec"), a copy of which is attached as Exhibit A hereto (the "Forbearance Letter"). Capitalized terms used in this letter and not otherwise defined herein shall have the meanings given to such terms in the Amended and Restated Revenue Interests Assignment Agreement among Ortec, OrCel LLC and PRF dated as of February 26, 2003 (as amended, supplemented or otherwise modified through the date hereof, the "RIA Agreement").
Forticell Bioscience Inc – Contract (December 14th, 2004)
EXHIBIT 10.1 December 13, 2004 Ortec International, Inc. 3960 Broadway New York, NY 10032 Attn: Ronald Lipstein, CEO Dear Mr. Lipstein: For the purpose of facilitating the ability of Ortec International, Inc. ("Ortec") to obtain funds in the future from a sale by Ortec of equity and/or the issuance by Ortec of debt and in reliance on the representation and agreement of Ortec set forth below, subject to the provisions of this letter, Paul Royalty Fund, L.P., formerly known as Paul Capital Royalty Acquisition Fund, L.P. ("PRF") agrees to forbear during the Forbearance Period (as defined herein) from exercising its rights under Section 5.07(a) of the Amended and Restated Revenue Interests Assignment Agreement among Ortec, Orcel LLC. and PRF dated as of February 26, 2003 (the "RIA Agreement") arising solely from either (x) the Purchase Option Event described in clause (v) only of the definition of "Purcha